A Bayesian approach to benefit-risk assessment in clinical studies with longitudinal data

被引:1
|
作者
Yan, Dongyan [1 ]
Ahn, Chul [2 ]
Azadeh, Shabnam [2 ]
Atlas, Mourad [2 ]
Tiwari, Ram [2 ]
机构
[1] Univ Missouri, Dept Stat, Columbia, MO 65211 USA
[2] FDA CDRH, Div Biostat, Silver Spring, MD USA
关键词
Dirichlet distribution; Dirichlet process; Gibbs sampling; log-odds ratio model; power prior; two-level multinomial; DISTRIBUTIONS; PROPOSAL; MODEL;
D O I
10.1080/10543406.2020.1726370
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Chuang-Stein et al. proposed a method for benefit-risk assessment by formulating a five-category multinomial random variable with the first four categories as a combination of benefit and risk, and the fifth category to include subjects who withdraw from study. In this article, we subdivide the single withdrawal category into four sub-categories to consider withdrawal for different reasons. To analyze eight-category data, we propose a two-level multivariate-Dirichlet Model to identify benefit-risk measures at the population level. For individual benefit-risk, we use a log-odds ratio model with Dirichlet process prior. Two methods are applied to a hypothetical clinical trial data for illustration.
引用
收藏
页码:574 / 591
页数:18
相关论文
共 50 条
  • [1] A Bayesian Approach for Benefit-Risk Assessment
    Zhao, Yueqin
    Zalkikar, Jyoti
    Tiwari, Ram C.
    LaVange, Lisa M.
    [J]. STATISTICS IN BIOPHARMACEUTICAL RESEARCH, 2014, 6 (04): : 326 - 337
  • [2] Bayesian Approach to Personalized Benefit-Risk Assessment
    Cui, Shiqi
    Zhao, Yueqin
    Tiwari, Ram C.
    [J]. STATISTICS IN BIOPHARMACEUTICAL RESEARCH, 2016, 8 (03): : 316 - 324
  • [3] A Bayesian approach to probabilistic sensitivity analysis in structured benefit-risk assessment
    Waddingham, Ed
    Mt-Isa, Shahrul
    Nixon, Richard
    Ashby, Deborah
    [J]. BIOMETRICAL JOURNAL, 2016, 58 (01) : 28 - 42
  • [4] The Case for a Bayesian Approach to Benefit-Risk Assessment:: Overview and Future Directions
    Costa, Maria J.
    He, Weili
    Jemiai, Yannis
    Zhao, Yueqin
    Di Casoli, Carl
    [J]. THERAPEUTIC INNOVATION & REGULATORY SCIENCE, 2017, 51 (05) : 568 - 574
  • [5] A Bayesian approach for individual-level drug benefit-risk assessment
    Li, Kan
    Luo, Sheng
    Yuan, Sammy
    Mt-Isa, Shahrul
    [J]. STATISTICS IN MEDICINE, 2019, 38 (16) : 3040 - 3052
  • [6] The Case for a Bayesian Approach to Benefit-Risk Assessment: Overview and Future Directions
    Maria J. Costa
    Weili He
    Yannis Jemiai
    Yueqin Zhao
    Carl Di Casoli
    [J]. Therapeutic Innovation & Regulatory Science, 2017, 51 : 568 - 574
  • [7] Bayesian approaches to benefit-risk assessment for diagnostic tests
    Bai, Tianyu
    Lan, Huang
    Tiwari, Ram
    [J]. JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2021, 31 (04) : 541 - 558
  • [8] On a Stepwise Quantitative Approach for Benefit-Risk Assessment
    He, Weili
    Sun, Yaxuan
    Li, Qing
    Wan, Sabrina
    [J]. THERAPEUTIC INNOVATION & REGULATORY SCIENCE, 2017, 51 (05) : 625 - 634
  • [9] On a Stepwise Quantitative Approach for Benefit-Risk Assessment
    Weili He
    Yaxuan Sun
    Qing Li
    Sabrina Wan
    [J]. Therapeutic Innovation & Regulatory Science, 2017, 51 : 625 - 634
  • [10] SEMIPARAMETRIC BAYESIAN MARKOV ANALYSIS OF PERSONALIZED BENEFIT-RISK ASSESSMENT
    Yan, Dongyan
    Guha, Subharup
    Ahn, Chul
    Tiwari, Ram
    [J]. ANNALS OF APPLIED STATISTICS, 2020, 14 (02): : 768 - 788